Navigation Links
New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment

FAS20013, a tuberculosis drug, currently in the experimental phase has offered hope in the treatment of multiple drug resistant and latent infections as well. The mechanism of action of the new drug is different // than those used for conventional treatment.

The drug targets slow growing mycobacteria involved in the disease process and induces selective killing of the same. The other drugs target a broad spectrum of non-pathogenic microorganisms that enables development of drug resistance. Nearly all isolates have been shown to be susceptible to the compound and no resistance has been observed.

The compound is the first ever known to combat latent infection. Following infection, some patients go into a latent phase where no symptoms are seen. Such patients are not capable of infecting others, as they do not have an active infection. However, they can develop active infection at any time. Worldwide, more than 2 billion people have this latent form of the disease.

Furthermore, the drug action is precipitated in just 4 hours while Rifampicin or Isoniazid needs 12 to 14 hours to destroy the pathogen. The pharmaceutical company FASgen, Inc., is working towards marketing the novel drug for commercial use.

Overcoming multiple drug resistance in tuberculosis represents a significant challenge in the successful treatment of tuberculosis. It is associated with a fatality rate ranging from 20 to 80%. The presence of an uncontrollable active infection and failure to respond to any therapy are strong indications for isolation of the patient to prevent the emergence of drug resistant strains in the population. In worst cases, it may be even required to perform surgical resection of a part of the lung. The cost associated with such a treatment can be as high as $250,000.

The drug is currently being investigated in laboratory animals to estimate the beneficial and toxic effects. An application would soon be submitted to th e Food and Drug Administration (FDA) regarding proceeding with clinical trials of the investigational new drug (IND). If promising results are obtained, we could soon have an anti-tuberculous drug for treatment of MDR-TB.


'"/>




Related medicine news :

1. Marijuana-Derived Drug Promises Hope In Treating Bladder Infection
2. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
3. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
4. Maternal Vitamin D Supplementation Promises Healthy Bones In Child
5. Raw Vegan Diet Promises Lightweight, Healthy Bones
6. Stem Cell Transplantation Promises Cure for Type 2 Diabetes
7. Health Minister Promises Strict Quality Control On Herbal Medicines
8. Anti-Cancer Treatment Promises Hope in Bird Flu Treatment
9. Nanotechnology Promises Huge Medical Benefits
10. Health Minister Promises New Benchmark for Wait Times
11. Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the ... dispensaries and head shops –can’t help but be heartened by the industry’s current surge. ... odor aptly described as “skunk smell.” At last they can simply, safely and ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South ... special report in the May issue of Consumer Reports focused on heart health. ... results achieved during and after coronary bypass and aortic valve replacement procedures. , ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... As part ... Museum today to honor the victims of the Holocaust and Nazi persecution, Center ... at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next ...
(Date:4/24/2017)... ... ... The California Dental Association Foundation’s two-day volunteer dental clinic, CDA Cares ... April 22-23 event at the San Mateo Event Center. , In addition to ... Cares educates the public and policymakers about the importance of good oral health and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology: